Shares of Nektar (NKTR) are moving higher after Sanofi (SNY) reported Phase 3 data for amlitelimab, its experimental treatment for atopic dermatitis. BofA said the readout came in “well short of investor expectations.” Shares of Nektar, which is developing rezpegaldesleukin to treat moderate-to-severe atopic dermatitis, are up 16%, or $4.62, to $33.17 in morning trading.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTR:
- Nektar Therapeutics’ Earnings Call Highlights Growth Potential
- Nektar price target raised to $98 from $90 at Oppenheimer
- Buy Rating for Nektar Therapeutics: Upcoming Catalysts and Strong Financial Performance
- Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments
- Nektar Therapeutics Reports Q2 2025 Financial Results